A significant amount of research has been conducted to examine the pathologic processes and epigenetic mechanisms contributing to peripheral hypertension. However, few studies have been carried out to understand the vascular remodeling behind pulmonary hypertension; they include peripheral artery (PA) muscularization, medial hypertrophy and neointima formation in proximal arteries, and plexiform lesion formation. Similarly, there is minimal research examining the epigenetic principles such as DNA methylation, histone modification, and miRNA regulation that contribute to vascular remodeling. Understanding these principles may be a key in developing new and more effective treatments for pulmonary hypertension. The purpose of this review is to summarize epigenetic research conducted in the field of hypertension that could possibly be used to understand the epigenetics of pulmonary hypertension. Possible future therapies that could be pursued using information from these studies include selective HDAC inhibitors (HDIs), exogenous administration of miRNAs, inhibitors for miRNA-21, miRNA-145, miRNA-138, and targeted DNA methyltransferases (DNMTs). All of these could potentially be used to silence pro-proliferative or anti-apoptotic genes that can lead to decreased SMC proliferation. Epigenetics may provide a glimmer of hope for the eventual improved treatment of this highly morbid and debilitating disease.